Roland Buesen
Bosch
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Roland Buesen.
Archives of Toxicology | 2014
Roland Buesen; Robert Landsiedel; Ursula G. Sauer; Wendel Wohlleben; Sibylle Groeters; Volker Strauss; Hennicke Kamp; Bennard van Ravenzwaay
AbstractnThe effects of seven nanomaterials (four amorphous silicon dioxides with or without surface functionalization, two surface-functionalized zirconium dioxides, and barium sulfate) upon 28-day oral exposure to male or female rats were investigated. The studies were performed as limit tests in accordance with OECD Test Guideline 407 applying 1,000xa0mg test substance/kg body weight/day. Additionally, the acute phase proteins haptoglobin and α2-macroglobulin as well as cardiac troponin I were determined, and metabolome analysis was performed in plasma samples. There were no test substance-related adverse effects for any of the seven nanomaterials. Moreover, metabolomics changes were below the threshold of effects. Since test substance organ burden was not analyzed, it was not possible to establish whether the lack of findings related to the absence of systemic exposure of the tested nanomaterials or if the substances are devoid of any potential for toxicity. The few published subacute oral or short-term inhalation studies investigating comparable nanomaterials (SiO2, ZrO2, and BaSO4) also do not report the occurrence of pronounced treatment-related findings. Overall, the results of the present survey provide a first indication that the tested nanomaterials neither cause local nor systemic effects upon subacute oral administration under the selected experimental conditions. Further investigations should aim at elucidating the extent of gastrointestinal absorption of surface-functionalized nanomaterials.n
Regulatory Toxicology and Pharmacology | 2011
B. van Ravenzwaay; Martina Dammann; Roland Buesen; Steffen Schneider
The Threshold Toxicological Concern (TTC) is based on the concept that reasonable assurance of safety can be given if exposure is sufficiently low. Originally based on the evaluation of carcinogenicity studies more recently TTC evaluations for other toxicological end points have been published. Here we report on the evaluation of our data base for oral developmental toxicity studies (OECD 414) in rats with 92 and 93 NOAEL values for maternal and developmental toxicity, respectively. The 5th percentile of the NOAEL distributions were calculated to be 4 mg/kg bw/d for maternal and 5mg/kg bw/d for developmental toxicity. Adding the data for developmental toxicity provided by Kroes et al. (2004), a joint evaluation of 111 individual NOAEL values resulted in a 5th percentile value of 4 mg/kg bw/d. Using a safety factor of 500 (to account for a possible underrepresentation of chemical classes) on the 5th percentile a TTC value for developmental toxicity of 8 μg/kg bw/d based on the combined data and for maternal toxicity of 8 μg/kg bw/d based on our data base was calculated. Within the REACH context this value may serve as guidance whether to perform an animal experiment or to rely on a TTC value if estimated exposure is sufficiently low.
Toxicology and Applied Pharmacology | 2009
Burkhard Flick; Chris E. Talsness; Rudolf Jäckh; Roland Buesen; Stephan Klug
N-methyl-2-pyrrolidone (NMP), which undergoes extensive biotransformation, has been shown in vivo to cause developmental toxicity and, especially after oral treatment, malformations in rats and rabbits. Data are lacking as to whether the original compound or one of its main metabolites is responsible for the toxic effects observed. Therefore, the relative embryotoxicity of the parent compound and its metabolites was evaluated using rat whole embryo culture (WEC) and the balb/c 3T3 cytotoxicity test. The resulting data were evaluated using two strategies; namely, one based on using all endpoints determined in the WEC and the other including endpoints from both the WEC and the cytotoxicity test. On basis of the first analysis, the substance with the highest embryotoxic potential is NMP, followed by 5-hydroxy-N-methyl-pyrrolidone (5-HNMP), 2-hydroxy-N-methylsuccinimide (2-HMSI) and N-methylsuccinimide (MSI). Specific dysmorphogeneses induced by NMP and 5-HNMP were aberrations in the head region of the embryos, abnormal development of the second visceral arches and open neural pores. The second evaluation strategy used only two endpoints of the WEC, i.e. the no observed adverse effect concentration (NOAEC(WEC)) and the lowest concentration leading to dysmorphogenesis in 100% of the cultured embryos (IC(Max WEC)). In addition to these WEC endpoints the IC(50 3T3) from the cytotoxicity test (balb/c 3T3 fibroblasts) was included in the evaluation scheme. These three endpoints were applied to a prediction model developed during a validation study of the European Centre for the Validation of Alternative Methods (ECVAM) allowing the classification of the embryotoxic potential of each compound into three classes (non-, weakly- and strongly embryotoxic). Consistent results from both evaluation strategies were observed, whereby NMP and its metabolites revealed a direct embryotoxic potential. Hereby, only NMP and 5-HNMP induced specific embryotoxic effects and were classified as weakly embryotoxic, whereas the other two metabolites, 2-HMSI and MSI, were determined to be non-embryotoxic.
Regulatory Toxicology and Pharmacology | 2017
Roland Buesen; Brian N. Chorley; Beatriz Silva Lima; George P. Daston; Lize Deferme; Timothy M. D. Ebbels; Timothy W. Gant; Amber K. Goetz; John M. Greally; Laura Gribaldo; Jörg Hackermüller; Bruno Hubesch; Danyel Jennen; Kamin J. Johnson; Jun Kanno; Hans-Martin Kauffmann; Madeleine Laffont; Patrick D. McMullen; Richard R. Meehan; Mark Pemberton; Stefania Perdichizzi; Aldert H. Piersma; Ursula G. Sauer; Kerstin Schmidt; Hervé Seitz; Kayo Sumida; Knut Erik Tollefsen; Weida Tong; Tewes Tralau; Ben van Ravenzwaay
Prevailing knowledge gaps in linking specific molecular changes to apical outcomes and methodological uncertainties in the generation, storage, processing, and interpretation of omics data limit the application of omics technologies in regulatory toxicology. Against this background, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) convened a workshop Applying omics technologies in chemicals risk assessment that is reported herein. Ahead of the workshop, multi-expert teams drafted frameworks on best practices for (i) a Good-Laboratory Practice-like context for collecting, storing and curating omics data; (ii) the processing of omics data; and (iii) weight-of-evidence approaches for integrating omics data. The workshop participants confirmed the relevance of these Frameworks to facilitate the regulatory applicability and use of omics data, and the workshop discussions provided input for their further elaboration. Additionally, the key objective (iv) to establish approaches to connect omics perturbations to phenotypic alterations was addressed. Generally, it was considered promising to strive to link gene expression changes and pathway perturbations to the phenotype by mapping them to specific adverse outcome pathways. While further work is necessary before gene expression changes can be used to establish safe levels of substance exposure, the ECETOC workshop provided important incentives towards achieving this goal.
Regulatory Toxicology and Pharmacology | 2012
B. van Ravenzwaay; Martina Dammann; Roland Buesen; Burkhard Flick; Steffen Schneider
The Threshold Toxicological Concern (TTC) is based on the concept that reasonable assurance of safety can be given if exposure is sufficiently low. We report on the evaluation of BASFs data for oral developmental toxicity studies in rabbits with 48 NOAEL values for maternal and developmental toxicity. The 5th percentile of the NOAEL distributions was calculated to be 5mg/kgbw/d for both maternal and developmental toxicity. From literature 56 compounds tested in rabbits were taken and combined with values from BASFs studies. The 5th percentile value for developmental toxicity of these 104 studies (mostly active ingredients) was 2mg/kgbw/d. Thus, a TTC value of 4μg/kgbw/d was calculated using a safety factor of 500 to account for relatively small database. This value is in the same range as the TTC value for developmental toxicity in rats of 8μg/kgbw/d. The lower value may serve as guidance to determine whether further evaluation is needed or whether to rely on a TTC value for industrial chemicals or low concentration (environmental) contaminants if exposure is sufficiently low. A comparison of 30 compounds tested at BASF in both species, suggests that rabbits are not more sensitive than rats. We encourage others to publish data on rabbit developmental toxicity.
Food and Chemical Toxicology | 2015
Roland Buesen; Stefan Schulte; V. Strauss; Silke Treumann; Matthias Becker; Sibylle Gröters; S. Carvalho; B. van Ravenzwaay
Astaxanthin, a naturally occurring xanthophyll, is commercially used as a coloring agent in salmon feed, but also marketed as a dietary supplement. The objective of this study was to investigate the subchronic toxicity of synthetic [3S, 3S]-Astaxanthin in rats. A powder formulation containing approximately 20% [3S, 3S]-Astaxanthin was administered via the diet to groups of 10 male and 10 female Wistar rats at concentrations of 5000, 15,000 and 50,000u2009ppm for a period of 13 weeks. A formulation of comparable composition but without [3S, 3S]-Astaxanthin served as a placebo control. There were no effects observed on survival, clinical examinations, clinical pathology, estrous cycle as well as on sperm parameters. At terminal necropsy, a macroscopically visible brown-blue discoloration of the gastrointestinal contents was noted which was considered to be secondary to the violet-brown color of the test material. No other significant or dose-related abnormalities were found in the tissues collected at termination. Our observations support that ingestion of [3S, 3S]-Astaxanthin of up to 700-920u2009mg/kg bw/day in rats in a gelatin/carbohydrate formulation is without adverse effects.
Regulatory Toxicology and Pharmacology | 2016
Achim Aigner; Roland Buesen; Tim W Gant; Nigel J. Gooderham; Helmut Greim; Jörg Hackermüller; Bruno Hubesch; Madeleine Laffont; Emma L. Marczylo; Gunter Meister; Jay S. Petrick; Reza J. Rasoulpour; Ursula G. Sauer; Kerstin Schmidt; Hervé Seitz; Frank J. Slack; Tokuo Sukata; Saskia M. van der Vies; Jan Verhaert; Kenneth W. Witwer; Alan Poole
The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology and as analytical and therapeutic agents. There was agreement that ncRNA expression profiling data requires careful evaluation to determine the utility of specific ncRNAs as biomarkers. To advance the use of ncRNA in regulatory toxicology, the following research priorities were identified: (1) Conduct comprehensive literature reviews to identify possibly suitable ncRNAs and areas of toxicology where ncRNA expression profiling could address prevailing scientific deficiencies. (2) Develop consensus on how to conduct ncRNA expression profiling in a toxicological context. (3) Conduct experimental projects, including, e.g., rat (90-day) oral toxicity studies, to evaluate the toxicological relevance of the expression profiles of selected ncRNAs. Thereby, physiological ncRNA expression profiles should be established, including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for cell homeostasis or pathogenesis, molecular events should be dose-dependently linked with substance-induced apical effects. Applying a holistic approach, knowledge on ncRNAs, omics and epigenetics technologies should be integrated into adverse outcome pathways to improve the understanding of the functional roles of ncRNAs within a regulatory context.
Epigenomics | 2017
John P. Thomson; Raffaele Ottaviano; Roland Buesen; Jonathan G. Moggs; Michael Schwarz; Richard R. Meehan
Aim Characterization of the hepatic epigenome following exposure to chemicals and therapeutic drugs provides novel insights into toxicological and pharmacological mechanisms, however appreciation of genome-wide inter- and intra-strain baseline epigenetic variation, particularly in under-characterized species such as the rat is limited. Material & methods To enhance the utility of epigenomic endpoints safety assessment, we map both DNA modifications (5-methyl-cytosine and 5-hydroxymethyl-cytosine) and enhancer related chromatin marks (H3K4me1 and H3K27ac) across multiple male and female rat livers for two important outbred laboratory rat strains (Sprague–Dawley and Wistar). Results & conclusion Integration of DNA modification, enhancer chromatin marks and gene expression profiles reveals clear gender-specific chromatin states at genes which exhibit gender-specific transcription. Taken together this work provides a valuable baseline liver epigenome resource for rat strains that are commonly used in chemical and pharmaceutical safety assessment.
Proceedings of the Symposium "Risk Assessment of Phytochemicals in Food - Novel Approaches", Kaiserslautern, Germany, 30 March-1 April 2009. | 2010
H. Kamp; Roland Buesen; E. Fabian; Michael Manfred Herold; G. Krennrich; E. Leibold; Ralf Looser; W. Mellert; T. Nishino; Alexandre Prokoudine; V. Strauss; Tilmann B. Walk; J. Wiemer; B. van Ravenzwaay
Toxicology Letters | 2016
M. Kemény; Heike Marxfeld; Roland Buesen; Amechi Chukwudebe; B. van Ravenzwaay; Ivana Fegert